CPTx Welcomes McDavid Stilwell as New Chief Financial Officer
CPTx GmbH, renowned for its pioneering efforts in developing therapies using single-stranded DNA, has appointed McDavid Stilwell as its Chief Financial Officer (CFO). This strategic move is expected to bolster CPTx's financial framework and operations as the company aims to propel its innovative pipeline of in vivo genetic medicines forward.
Driving Strategic Financial Leadership
Mr. Stilwell's vast experience spans over two decades in finance, corporate development, investor relations, and communications, which makes him an invaluable asset for CPTx. His primary focus will be overseeing the company’s financial strategy and operations, along with managing the investor relations and business development sectors. Such initiatives are crucial as CPTx aspires to transition its in vivo CAR-T program into clinical development by 2027 and ensure its novel gene nanocarrier is ready for partnerships in 2026.
“I am excited to help lead the CPTx team to apply their expertise in single-stranded DNA technology to develop in vivo genetic medicines that overcome delivery and access challenges of current cell and gene therapies,” stated Mr. Stilwell. His emphasis on making cell and gene therapies more accessible and patient-friendly aligns perfectly with CPTx's mission. The company aims to achieve a breakthrough in therapies designed to treat blood cancers and autoimmune diseases effectively.
Alignment with Corporate Vision
CEO Hendrik Dietz expressed his enthusiasm about Mr. Stilwell’s appointment, stating that it significantly enhances their executive capabilities. In early 2024, Dr. Grant Boldt joined CPTx as Chief Operating Officer (COO), bringing a wealth of operational experience to the company. With Mr. Stilwell onboard, CPTx is poised to make pivotal advancements in its lead development programs.
“McDavid’s extensive background in biopharma finance and corporate strategy will undoubtedly strengthen our leadership as we progress toward clinical development and establish formal partnerships,” Dr. Dietz remarked.
A Track Record of Success
Prior to joining CPTx, Mr. Stilwell served as the CFO at Coherus Biosciences, where he successfully led the launch of multiple products in the U.S. market. With prior leadership roles at innovative biotech firms like Sangamo Therapeutics, known for its gene-editing technologies, Mr. Stilwell's credentials position him well to support CPTx in navigating the complexities of the biopharmaceutical landscape.
Furthermore, Mr. Stilwell's previous experience as a Senior Investment Analyst at Shadwell Capital adds another layer of financial expertise that will benefit CPTx's strategic financial objectives.
Mr. Stilwell holds a Bachelor's degree from St. John's College and an MBA from Harvard Business School, further consolidating his qualifications as a leader in the biotech financial sector.
About CPTx
Founded on over 15 years of groundbreaking research from the Technical University of Munich, CPTx is at the forefront of advancing global health through innovative medicines. The company specializes in developing in vivo genetic therapies utilizing single-stranded DNA technology. CPTx is currently focused on progressing its cutting-edge CAR-T therapy through preclinical development, with an expected Investigational New Drug (IND) filing in 2027. Additionally, the organization is working on a unique self-delivering gene nanocarrier designed to safely and effectively target specific cell types.
With its headquarters in Munich and a U.S. subsidiary in South San Francisco, CPTx is set to redefine access to gene therapies, ensuring that effective medical treatments reach all patients in need.
For more information, visit
CPTx's website.